The ADRD Training Program has enlisted the participation of the following faculty as Mentors, due to their expertise in the following fields:
- Cellular, computational & animal modeling of addiction, aging, hypoxia, AD, FTD, ALS, & PD
- Neurodegeneration & inflammation
- Cognition & aging
- Addiction, psychiatric & behavioral disorders, sleep & hypoxia
- Neuropathology & neuroimaging
- Genetics, RNA biology & viral transduction
- Use of large-scale, open-format databases
- Clinical diagnostics, clinical neuropsychology & behavioral interventions of AD & overlapping conditions
Jose Abisambra, PhD
Identifying mechanisms of tau-mediated neurodegeneration in tauopathies.
Russel Bauer, PhD
Structure-function relationships in memory disorders using structural brain imaging techniques.
Jennifer Bizon, PhD
Mechanisms of brain aging and the implications for cognitive function.
David Borchelt, PhD
Modeling neurodegeneration and protein misfolding in ADRD.
Dawn Bowers, PhD
Neuropsychology of cognition and emotion.
Sara Burke, PhD
Uncovering mechanisms of age-related impairments in ADRD.
Paramita Chakrabarty, PhD
Understanding the role of immune activation in neurodegeneration.
Ronald Cohen, PhD
Discovering ways of delaying or ameliorating normal cognitive aging — cognitive decline not caused by disease.
Thomas Foster, PhD
Identifying mechanisms for age-related memory impairment and to test treatments to alleviate memory deficits.
Benoit Giasson, PhD
Understanding the regulation of protein interactions and folding that affect protein aggregation in the nervous system.
Habibeh Khoshbouei, PharmD, PhD
Identifying novel mechanisms involved in regulation of dopamine neurotransmission in the brain.
Matthew Farrer, PhD
Genetic and functional analysis of neurologic and neurodegenerative disorders.
Marcelo Febo, PhD
Our laboratory uses magnetic resonance imaging to measure in vivo functional and microstructure changes in mouse models of Alzheimer’s disease and related dementias.
Jada Lewis, PhD
Creating, characterizing, and utilizing genetically manipulated in vivo models of neurodegenerative diseases.
Carol Mathews, MD
Identifying the causes and neural underpinnings of obsessive compulsive and anxiety spectrum disorders.
Andrew Maurer, PhD
Understanding how the brain rapidly translates environmental information into complex representations in support of cognitive function.
Gordon Mitchell, PhD
Identifying fundamental mechanisms of spinal respiratory motor plasticity induced by intermittent hypoxia, and attempts to harness that plasticity to treat devastating clinical disorders that compromise breathing and non-respiratory limb movements, such as cervical spinal injury and ALS.
Sara Jo Nixon, PhD
Examining the acute and chronic effects of alcohol and other drugs.
Michael Okun, MD
Exploring the cognitive, behavioral, and mood effects of deep brain stimulation (DBS)
Catherine Price, PhD
Examining the predictive value of patients’ white and gray matter structure integrity on disease associated cognitive decline and vulnerability to cognitive change after elective medical interventions with anesthesia.
Laura Ranum, PhD
Utilizing models to understand how genetic mutations cause neurodegenerative diseases.
Diego Rincon-Limas, PhD
Development and application of new technologies to define the molecular pathways leading to neurodegeneration and identification of potential therapeutic targets
Barry Setlow, PhD
Investigating how acute and chronic exposure to drugs of abuse affects cognitive and motivational outcomes.
Glenn Smith, PhD
Early detection of neurodegenerative diseases and the methods to prevent or delay the development of dementia.
Maurice Swanson, PhD
How RNA processing is regulated during embryonic, fetal and postnatal development and how this regulation is disrupted in neurological disease, particularly in microsatellite expansion disorders.
Eric Wang, PhD
His lab is focused on three main areas – 1) studying the pathogenesis of microsatellite repeat diseases, in particular myotonic dystrophy, 2) studying the basics of how RNA is processed and localized in cells in tissues, and 3) combining insights made in both of those areas to develop treatments for people with these diseases.
Daniel Wesson, PhD
Testing specific hypotheses regarding the neural basis of sensory dysfunction in neurological disorders, including dementias and addiction, wherein sensory processing is aberrant.
Adam Woods, PhD
Identify and implement methods of non-invasive neuromodulation interventions to make a meaningful impact on age-related conditions and disorders.
ALZHEIMER'S T32 Mentoring Faculty
Need to submit or update your bio?